...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Digestive Diseases and Sciences >Direct-acting antiviral therapy for hepatitis C: attitudes regarding future use.
【24h】

Direct-acting antiviral therapy for hepatitis C: attitudes regarding future use.

机译：丙型肝炎的直接作用抗病毒治疗：关于未来使用的态度。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Response to current therapy of hepatitis C virus (HCV) is suboptimal. Direct-acting antiviral therapies (DAA) are expected to improve treatment outcomes. Additional treatments for HCV will invariably make therapeutic choices and patient management more complex. We hypothesize that current perceptions regarding the complexity of DAA therapy will influence attitudes towards future use by practitioners who are currently treating HCV. METHODS: An Internet-based survey was sent to 10,082 AASLD and AGA members to determine if they treat HCV infection, their knowledge of DAA therapies, attitudes towards current and future HCV treatments, and if they participated in clinical trials using DAA agents. RESULTS: Out of a total of 1,757 individuals responding to the survey, 75% treat HCV; 79% were MDs, 67% were Gastroenterologists, and 24% were Hepatologists. Of the respondents, 77% indicated they were "very aware" or "aware" of DAA therapies, 20% participated in clinical trials, and 3% had minimal knowledge of DAA agents. Comparing treatment today = 0.0054), 6 vs. 10% would refer to an "HCV expert" (p = 0.016), and 1% would refer to an ID specialist. Of respondents with "minimal knowledge" of DAA, 52% stated that they would use them in the future. CONCLUSIONS: Although the majority of respondents appear ready to utilize DAA agents in the future, referrals to hepatitis C experts knowledge" of DAA therapies also appear to be willing to utilize these compounds, raising concerns regarding their inappropriate use. Broad education of healthcare providers to prevent inappropriate use of these agents will be critical.
机译：简介：对当前丙型肝炎病毒（HCV）治疗的反应欠佳。直接作用抗病毒疗法（DAA）有望改善治疗效果。 HCV的其他治疗将始终使治疗选择和患者管理更加复杂。我们假设当前对DAA治疗复杂性的看法将影响当前正在治疗HCV的从业者对未来使用的态度。方法：向10,082名AASLD和AGA成员发送了基于Internet的调查，以确定他们是否治疗HCV感染，对DAA治疗的了解，对当前和未来HCV治疗的态度以及是否参加了使用DAA药物的临床试验。结果：在接受调查的1757名患者中，有75％的患者治疗HCV。医学博士占79％，胃肠病学家占67％，肝病学家占24％。在受访者中，有77％的人表示他们对DAA疗法“非常了解”或“知道”，有20％的人参加了临床试验，有3％的人对DAA剂的了解最少。今天比较的治疗= 0.0054），“ HCV专家”为6比10％（p = 0.016），ID专家为1％。在对DAA有“最少了解”的受访者中，有52％的受访者表示他们将来会使用它们。结论：尽管大多数受访者似乎准备在将来使用DAA药物，但转介到DAA疗法的丙型肝炎专家知识“似乎也愿意使用这些化合物，这引起了对它们不当使用的担忧。防止不恰当地使用这些代理将至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号